 Jennifer Rosen
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 9 | 2022 | 343 | 2.640 |
Why?
| | Thyroidectomy | 11 | 2022 | 90 | 2.030 |
Why?
| | Thyroid Nodule | 6 | 2021 | 56 | 1.770 |
Why?
| | Thyroxine | 2 | 2022 | 64 | 1.340 |
Why?
| | Complementary Therapies | 3 | 2014 | 94 | 1.110 |
Why?
| | Parathyroidectomy | 2 | 2024 | 9 | 1.030 |
Why?
| | Hyperparathyroidism, Primary | 2 | 2024 | 7 | 1.030 |
Why?
| | Surgeons | 2 | 2025 | 338 | 0.800 |
Why?
| | Goals | 1 | 2025 | 180 | 0.800 |
Why?
| | General Surgery | 2 | 2025 | 207 | 0.780 |
Why?
| | Mentors | 1 | 2025 | 218 | 0.770 |
Why?
| | Hormone Replacement Therapy | 2 | 2022 | 106 | 0.740 |
Why?
| | Mentoring | 1 | 2025 | 163 | 0.730 |
Why?
| | Thyroid Gland | 3 | 2019 | 88 | 0.650 |
Why?
| | Vulnerable Populations | 2 | 2022 | 173 | 0.600 |
Why?
| | Hypothyroidism | 1 | 2019 | 67 | 0.590 |
Why?
| | Social Determinants of Health | 2 | 2022 | 299 | 0.500 |
Why?
| | Sociological Factors | 1 | 2016 | 6 | 0.490 |
Why?
| | Spectrum Analysis | 2 | 2013 | 93 | 0.460 |
Why?
| | Delivery of Health Care | 2 | 2022 | 940 | 0.460 |
Why?
| | Carcinoma, Medullary | 1 | 2015 | 16 | 0.440 |
Why?
| | Safety-net Providers | 1 | 2016 | 124 | 0.430 |
Why?
| | Emergency Medical Services | 1 | 2022 | 696 | 0.430 |
Why?
| | Overweight | 1 | 2019 | 606 | 0.420 |
Why?
| | Kelp | 1 | 2014 | 2 | 0.420 |
Why?
| | Phytotherapy | 1 | 2014 | 74 | 0.400 |
Why?
| | Graves Disease | 2 | 2013 | 30 | 0.390 |
Why?
| | Cytological Techniques | 1 | 2013 | 28 | 0.390 |
Why?
| | Robotics | 1 | 2014 | 87 | 0.390 |
Why?
| | Benchmarking | 1 | 2014 | 188 | 0.390 |
Why?
| | Integrative Medicine | 1 | 2013 | 17 | 0.380 |
Why?
| | Thyroid Diseases | 1 | 2013 | 43 | 0.380 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2014 | 192 | 0.380 |
Why?
| | Adenoma, Oxyphilic | 1 | 2010 | 7 | 0.340 |
Why?
| | Carcinoma, Papillary | 1 | 2010 | 78 | 0.320 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2009 | 14 | 0.310 |
Why?
| | Humans | 37 | 2025 | 144261 | 0.310 |
Why?
| | Intussusception | 1 | 2009 | 25 | 0.310 |
Why?
| | Iodine Radioisotopes | 3 | 2022 | 136 | 0.310 |
Why?
| | Neoplasms | 2 | 2016 | 2870 | 0.310 |
Why?
| | Colonic Diseases | 1 | 2009 | 34 | 0.300 |
Why?
| | Laparoscopy | 1 | 2014 | 475 | 0.300 |
Why?
| | Parathyroid Neoplasms | 2 | 2008 | 12 | 0.300 |
Why?
| | Middle Aged | 15 | 2024 | 35762 | 0.300 |
Why?
| | Health Services Accessibility | 2 | 2017 | 1091 | 0.280 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 132 | 0.280 |
Why?
| | Female | 21 | 2025 | 77976 | 0.250 |
Why?
| | Adult | 14 | 2024 | 40262 | 0.250 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 878 | 0.240 |
Why?
| | Retrospective Studies | 11 | 2024 | 17009 | 0.240 |
Why?
| | Male | 19 | 2025 | 72035 | 0.240 |
Why?
| | Obesity | 1 | 2019 | 3057 | 0.240 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6021 | 0.230 |
Why?
| | Quality of Health Care | 3 | 2015 | 688 | 0.230 |
Why?
| | Parathyroid Glands | 1 | 2005 | 11 | 0.230 |
Why?
| | Aged | 11 | 2024 | 25850 | 0.210 |
Why?
| | Hospitalization | 4 | 2018 | 2424 | 0.210 |
Why?
| | Health Care Surveys | 3 | 2015 | 538 | 0.200 |
Why?
| | Lymphatic Metastasis | 2 | 2022 | 333 | 0.200 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2023 | 74 | 0.190 |
Why?
| | Adenoma | 1 | 2005 | 218 | 0.190 |
Why?
| | Socioeconomic Factors | 3 | 2017 | 1312 | 0.180 |
Why?
| | Program Evaluation | 2 | 2025 | 946 | 0.180 |
Why?
| | Nursing Staff, Hospital | 2 | 2015 | 158 | 0.180 |
Why?
| | Data Accuracy | 1 | 2022 | 65 | 0.180 |
Why?
| | Time-to-Treatment | 1 | 2024 | 240 | 0.180 |
Why?
| | Postoperative Complications | 3 | 2022 | 2916 | 0.180 |
Why?
| | Scattering, Radiation | 2 | 2013 | 102 | 0.180 |
Why?
| | Endocrine Surgical Procedures | 1 | 2021 | 2 | 0.180 |
Why?
| | Disinfection | 1 | 2023 | 129 | 0.170 |
Why?
| | Genomics | 1 | 2006 | 833 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2015 | 40 | 0.170 |
Why?
| | Housing | 1 | 2022 | 144 | 0.170 |
Why?
| | Endocrinology | 1 | 2021 | 75 | 0.160 |
Why?
| | Combined Modality Therapy | 2 | 2014 | 1264 | 0.160 |
Why?
| | Multivariate Analysis | 2 | 2022 | 1533 | 0.160 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1782 | 0.160 |
Why?
| | Hashimoto Disease | 1 | 2020 | 10 | 0.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1953 | 0.150 |
Why?
| | Healthcare Disparities | 2 | 2017 | 725 | 0.150 |
Why?
| | Pilot Projects | 1 | 2025 | 1867 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2023 | 487 | 0.150 |
Why?
| | Lymph Nodes | 1 | 2022 | 502 | 0.150 |
Why?
| | United States | 8 | 2018 | 15876 | 0.150 |
Why?
| | Physician-Patient Relations | 2 | 2014 | 581 | 0.140 |
Why?
| | Neck Dissection | 1 | 2018 | 17 | 0.140 |
Why?
| | Health Services Research | 3 | 2017 | 394 | 0.140 |
Why?
| | Prospective Studies | 2 | 2025 | 7970 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2926 | 0.130 |
Why?
| | Professional Practice | 2 | 2015 | 57 | 0.130 |
Why?
| | Young Adult | 6 | 2018 | 13990 | 0.130 |
Why?
| | Hospital Mortality | 2 | 2018 | 1027 | 0.120 |
Why?
| | Machine Learning | 1 | 2022 | 585 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2014 | 11643 | 0.120 |
Why?
| | Minority Groups | 1 | 2018 | 277 | 0.120 |
Why?
| | Boston | 1 | 2016 | 92 | 0.120 |
Why?
| | Clinical Competence | 1 | 2024 | 1241 | 0.120 |
Why?
| | Personnel Administration, Hospital | 1 | 2015 | 2 | 0.120 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 79 | 0.120 |
Why?
| | Case-Control Studies | 1 | 2023 | 3592 | 0.120 |
Why?
| | Hospitals, Urban | 1 | 2016 | 144 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 3313 | 0.110 |
Why?
| | Health Status Disparities | 1 | 2018 | 321 | 0.110 |
Why?
| | Surgical Instruments | 1 | 2014 | 51 | 0.100 |
Why?
| | Thymus Hyperplasia | 1 | 2013 | 1 | 0.100 |
Why?
| | Cohort Studies | 3 | 2020 | 5935 | 0.100 |
Why?
| | Germ-Line Mutation | 1 | 2015 | 172 | 0.100 |
Why?
| | Weight Loss | 1 | 2019 | 832 | 0.100 |
Why?
| | Lymph Node Excision | 1 | 2015 | 173 | 0.100 |
Why?
| | Myocardial Infarction | 2 | 2018 | 1208 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 219 | 0.100 |
Why?
| | Comprehensive Health Care | 1 | 2013 | 22 | 0.100 |
Why?
| | Hand Strength | 1 | 2014 | 143 | 0.100 |
Why?
| | Cadaver | 1 | 2014 | 304 | 0.100 |
Why?
| | Comparative Effectiveness Research | 1 | 2014 | 169 | 0.100 |
Why?
| | History, 20th Century | 1 | 2014 | 324 | 0.100 |
Why?
| | Hand | 1 | 2014 | 161 | 0.100 |
Why?
| | Algorithms | 2 | 2013 | 1834 | 0.090 |
Why?
| | Poverty | 1 | 2016 | 523 | 0.090 |
Why?
| | Telemedicine | 1 | 2021 | 940 | 0.090 |
Why?
| | Genetic Testing | 1 | 2015 | 478 | 0.090 |
Why?
| | Risk | 1 | 2014 | 909 | 0.090 |
Why?
| | Workplace | 1 | 2014 | 274 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 1137 | 0.090 |
Why?
| | Medical Oncology | 1 | 2014 | 331 | 0.090 |
Why?
| | Postoperative Care | 1 | 2013 | 288 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1812 | 0.080 |
Why?
| | Body Mass Index | 1 | 2019 | 2420 | 0.080 |
Why?
| | Hospitals | 1 | 2015 | 727 | 0.080 |
Why?
| | Preoperative Care | 1 | 2013 | 379 | 0.080 |
Why?
| | Self Care | 1 | 2013 | 388 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8243 | 0.080 |
Why?
| | Principal Component Analysis | 1 | 2010 | 197 | 0.080 |
Why?
| | Light | 1 | 2013 | 410 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3166 | 0.080 |
Why?
| | Antithyroid Agents | 1 | 2009 | 12 | 0.080 |
Why?
| | Etoposide | 1 | 2009 | 166 | 0.070 |
Why?
| | Decision Trees | 1 | 2009 | 81 | 0.070 |
Why?
| | Cyclophosphamide | 1 | 2009 | 266 | 0.070 |
Why?
| | Vincristine | 1 | 2009 | 140 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2009 | 117 | 0.070 |
Why?
| | Self Report | 1 | 2013 | 863 | 0.070 |
Why?
| | Prednisone | 1 | 2009 | 221 | 0.070 |
Why?
| | Sacrococcygeal Region | 1 | 2008 | 6 | 0.070 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2008 | 1 | 0.070 |
Why?
| | Internet | 1 | 2013 | 698 | 0.070 |
Why?
| | Databases, Factual | 1 | 2014 | 1484 | 0.070 |
Why?
| | Diagnostic Tests, Routine | 1 | 2009 | 108 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2013 | 777 | 0.070 |
Why?
| | Genes, Homeobox | 1 | 2008 | 50 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2008 | 63 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2111 | 0.070 |
Why?
| | Risk Factors | 1 | 2022 | 10699 | 0.070 |
Why?
| | Patient Care Team | 1 | 2013 | 686 | 0.070 |
Why?
| | Doxorubicin | 1 | 2009 | 397 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1182 | 0.060 |
Why?
| | Adolescent | 4 | 2018 | 22281 | 0.060 |
Why?
| | Goiter, Nodular | 1 | 2006 | 2 | 0.060 |
Why?
| | Sodium Pertechnetate Tc 99m | 1 | 2006 | 4 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2013 | 847 | 0.060 |
Why?
| | Teratoma | 1 | 2008 | 120 | 0.060 |
Why?
| | Disease Progression | 1 | 2015 | 2840 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 68 | 0.060 |
Why?
| | Medical History Taking | 1 | 2006 | 115 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 787 | 0.060 |
Why?
| | Thyrotropin | 1 | 2006 | 118 | 0.060 |
Why?
| | Diabetic Angiopathies | 2 | 2018 | 254 | 0.060 |
Why?
| | Biopsy, Needle | 1 | 2006 | 183 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 623 | 0.060 |
Why?
| | Prognosis | 1 | 2015 | 4278 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 1983 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 3 | 2013 | 2730 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2008 | 623 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5813 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1347 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2005 | 519 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1682 | 0.050 |
Why?
| | Medicare | 1 | 2009 | 881 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 758 | 0.050 |
Why?
| | Down-Regulation | 1 | 2005 | 627 | 0.050 |
Why?
| | Ultrasonography | 1 | 2006 | 768 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1487 | 0.050 |
Why?
| | Kidney Failure, Chronic | 2 | 2018 | 597 | 0.050 |
Why?
| | Up-Regulation | 1 | 2005 | 851 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2023 | 387 | 0.040 |
Why?
| | Reoperation | 1 | 2022 | 629 | 0.040 |
Why?
| | Prophylactic Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
| | Skin | 1 | 2023 | 754 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 397 | 0.030 |
Why?
| | Propensity Score | 1 | 2019 | 367 | 0.030 |
Why?
| | Acculturation | 1 | 2017 | 54 | 0.030 |
Why?
| | Insurance Claim Review | 1 | 2017 | 82 | 0.030 |
Why?
| | California | 1 | 2018 | 469 | 0.030 |
Why?
| | Mutation | 1 | 2008 | 4085 | 0.030 |
Why?
| | American Hospital Association | 1 | 2015 | 9 | 0.030 |
Why?
| | Hospital Bed Capacity | 1 | 2015 | 28 | 0.030 |
Why?
| | Organizational Culture | 1 | 2015 | 162 | 0.030 |
Why?
| | Role | 1 | 2014 | 29 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1028 | 0.030 |
Why?
| | Hospital Administration | 1 | 2014 | 26 | 0.030 |
Why?
| | Social Environment | 1 | 2015 | 254 | 0.030 |
Why?
| | Quality Improvement | 1 | 2022 | 1285 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 371 | 0.020 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 129 | 0.020 |
Why?
| | Length of Stay | 1 | 2019 | 1335 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2104 | 0.020 |
Why?
| | Cough | 1 | 2013 | 124 | 0.020 |
Why?
| | Environment | 1 | 2014 | 305 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3403 | 0.020 |
Why?
| | Leadership | 1 | 2015 | 408 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2815 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2013 | 320 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1075 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3637 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1254 | 0.020 |
Why?
| | Stroke | 1 | 2018 | 1254 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2013 | 707 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 981 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2008 | 1455 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2008 | 2829 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2359 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3857 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 7180 | 0.010 |
Why?
|
|
Rosen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|